Navigation Links
Cancer drugs in the pipeline
Date:12/11/2008

SAN ANTONIO - Scientists in the clinic and the laboratory continue to work to drive breast cancer mortality rates down with breakthrough drugs. With tamoxifen's discovery 30 years behind us, and the impact of Herceptin still being felt, researchers are studying zoledronic acid, aromatase inhibitors and monoclonal antibodies, among others, with encouraging results. Data will be presented at the CTRC-AACR San Antonio Breast Cancer Symposium.


Zoledronic Acid May Have Anti-Tumor Properties
Abstract #5101, Robert Coleman, M.D

Early results of the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial suggest that zoledronic acid may have antitumor properties when combined with chemotherapy. Treatment was linked with a reduction in tumor size (20.5 mm vs. 30 mm), an increase in the complete response rate (10.9 percent vs. 5.8 percent) and a decrease in the number of patients requiring mastectomy (65.3 percent vs. 77.9 percent).

Full release available/Complete data to be presented at the meeting.


Breast Cancer Patients May have Better Option to Reduce Estrogen Levels
Abstract #15, Stephen Jones, M.D
Embargo: 10:15 a.m. CST, December 11, 2008

Despite adjuvant therapy to reduce estrogen levels, one in five breast cancer survivors will have a recurrence. The first results from the TEAM study, one of the largest clinical trials ever conducted for invasive breast cancer, demonstrated that exemestane may be more effective in postmenopausal women than current treatment with tamoxifen. Exemestane is an agent that actually stops the body from producing estrogen.

Full data to be presented at the meeting.


Herceptin Increases Event-Free Survival in Locally Advanced HER2-Postive Breast Cancer
Abstract #31, Luca Gianni, M.D

Among patients with HER2-positive, locally advanced breast cancer, neoadjuvant treatment with Herceptin increased three-year, event-free survival to 70 percent compared with 53 percent among those receiving chemotherapy alone. The addition of trastuzumab (Herceptin) was well tolerated with acceptable cardiac safety. Researchers claim this phase III clinical trial establishes chemotherapy with one year of Herceptin as a standard treatment option in this patient population.

Full data to be presented at the meeting.


Lapatinib Improved Progression-Free Survival in Postmenopausal Women with Breast Cancer
Abstract #46, Stephen Johnston, Ph.D

For the treatment of women with hormone-receptor-positive metastatic breast cancer that also co-expressed HER2, combining lapatinib with an aromatase inhibitor significantly improved progression-free survival from three months in the letrozole alone group to 8.2 months in the combination group. Overall clinical benefit rate increased from 28.7 percent to 48.7 percent. Involving 1,286 patients, this is the largest trial of its kind to date.

Full data to be presented at the meeting.


Adjuvant Aromatase Inhibitors Lower Breast Cancer Recurrence Risk
Abstract #12, James Ingle, M.D.
Embargo: 9:30 a.m. CST, December 11, 2008

Adjuvant therapy with aromatase inhibitors (AIs) for postmenopausal estrogen-receptor-positive breast cancer given either as initial monotherapy or after several years of tamoxifen decreases the risk of recurrent disease more than tamoxifen, according to two meta-analyses. The risk reduction with AIs was statistically significant.

Full data to be presented at the meeting.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
2. Pilots May Face Greater Cancer Risk
3. Estrogen pills can benefit women with metastatic breast cancer
4. Light shines for potential early cancer diagnosis technique
5. LegalView Reports That Skin Cancer Drug May Offer Treatment to Mesothelioma Patients
6. PADRES Contra El Cancer to Host its 10th Annual Posada Holiday Celebration for Children with Cancer
7. UBC researchers discover gene mutation that causes eye cancer
8. Treadmill Desks More Effective in Decreasing Prostate Cancer Risks Than Vitamin and Antioxidant Supplements
9. Hormone therapy for prostate cancer does not appear to increase cardiac deaths
10. Oral cancer patients could be diagnosed earlier
11. PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... ... provider in the modern ART laboratory, to provide hands-on training utilizing cutting-edge equipment ... , NextGen LifeLabs, a MedTech Group Purchasing vendor , will provide specialized ...
(Date:5/23/2017)... ... May 23, 2017 , ... Orbita’s Nathan Treloar will discuss the ... in San Francisco. Titled Connected Health and IoT: Technology Innovators and Disruption , ... by Parks Associates, a market research and consulting firm specializing in emerging consumer technology ...
(Date:5/23/2017)... ... May 23, 2017 , ... Therachat , a smart guided ... an infographic on the current state of anxiety in support of National Mental Health ... conducted in April 2017 and benchmarked general anxiety levels as well as identified the ...
(Date:5/22/2017)... Mt. Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced ... can be administered for a variety of treatments. One or more sedation methods may ...
(Date:5/22/2017)... ... 22, 2017 , ... An inventor from Columbia, S.C., wants to offer people ... was damaged in a firework accident, so she couldn’t grip a pen properly," he ... He then designed and created a prototype for the HELPEN HAND, a special pen ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... SKANEATELES FALLS, N.Y. , May 5, 2017 /PRNewswire/ ... expansion that will add approximately 100,000 square feet to ... announced in September 2016 its commitment to bring more ... York , where Welch Allyn has maintained a ... facility will help accommodate these new positions, a large ...
(Date:5/4/2017)... SAN DIEGO , May 4, 2017 ... 2017 Annual Clinical and Scientific Meeting— OBP Medical , ... devices, today announced the launch of a new extra-small ... and ER-SPEC vaginal specula. Already available ... and extra-large sizes makes OBP Medical,s line of single-use ...
(Date:5/3/2017)... Calif. , May 3, 2017 ... of any hospital or healthcare facility. Commonly referred ... room is equipped with diagnostic imaging technology to ... of the heart. In these spaces, a team ... catheterization, balloon angioplasty, percutaneous coronary intervention, congenital heart ...
Breaking Medicine Technology: